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Abstract
Recent findings regarding Dll4 function in physiological and pathological conditions indicate that this Notch ligand may
constitute an important therapeutic target. Dll4 appears to be a major anti-angiogenic agent, occupying a central role in
various angiogenic pathways. The first trials of anti-Dll4 therapy in mice demonstrated a paradoxical effect, as it reduced
tumor perfusion and growth despite leading to an increase in vascular density. This is seen as the result of insufficient
maturation of the newly formed vasculature causing a circulatory defect and increased tumor hypoxia. As Dll4 function is
known to be closely dependent on expression levels, we envisioned that the therapeutic anti-Dll4 dosage could be
modulated to result in the increase of adequately functional blood vessels. This would be useful in conditions where
vascular function is a limiting factor for recovery, like wound healing and tissue hypoxia, especially in diabetic patients. Our
experimental results in mice confirmed this possibility, revealing that low dosage inhibition of Dll4/Notch signaling causes
improved vascular function and accelerated wound healing.
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Introduction
Wound healing is a physiological process required for
maintenance of an intact skin barrier. Angiogenesis, the growth
of new blood vessels, is an important natural process required for
healing wounds and for restoring blood flow to tissues after injury
or insult [1]. Following a traumatic injury, angiogenesis is initiated
by multiple molecular signals, including hemostatic factors,
inflammation, cytokine growth factors, and cell-matrix interac-
tions, and is mediated throughout the entire wound-healing
process [2,3]. New blood vessels grow via a cascade of biological
events to form granulation tissue in the wound bed [4]. This
process is sustained until the terminal stages of healing, when
angiogenesis is slowed by reduced levels of growth factors,
resolution of inflammation, stabilized tissue matrix, and endoge-
nous inhibitors of angiogenesis [2,3]. Defects in the angiogenesis
pathway impair granulation and delay healing [4].
Because angiogenesis is required for wound healing, its
induction is beneficial in many clinical situations to achieve
wound closure, enhance tissue vascularization, improve local
circulation, and promote healing and regeneration. This capability
is controlled by pro- and anti-angiogenic factors present
throughout the body. A precise physiological balance exists
between pro-angiogenic and endogenous anti-angiogenic inhibi-
tors, such that vascular growth is normally suppressed. Immedi-
ately following injury, however, pro-angiogenic factors are
released into the wound bed, and a shift occurs in the balance
of regulators favoring vascular growth [2,3,5,6,7].
There are already a few pro-angiogenic therapies available for
use in the treatment of wounds. The first drug of this kind was the
recombinant human platelet-derived growth factor-BB (rhPDGF-
BB), which produces good clinical results [8]. A number of
angiogenic growth factors are in pre-clinical and clinical
development for wound healing, including vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF), keratinocyte
growth factor (KGF), and transforming growth factor-beta (TGF-
b). Although PDGF-BB was the first growth factor to become
clinically approved for wound care, it is likely that multiple growth
factors will eventually become available and that combination
therapy may be beneficial [7].
Dll4 is an endothelium-specific Notch ligand [9]. Dll4 is largely
an arterial-endothelial-specific gene, especially during embryonic
development, while in adults its expression is mostly restricted to
small arteries and capillary networks [10,11]. Haploinsufficiency of
Dll4 in mice results in embryonic lethality at approximately E10,5
due to defective vascular development [10]. Notably, Dll4 and Vegf
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due to failure to form a functional vasculature.
Recently, several groups have investigated whether inhibition of
the Dll4/Notch pathway might affect tumor angiogenesis and
growth. Notch pathway blockade was achieved with either a Dll4-
selective neutralizing antibody or a soluble Dll4 fusion protein
(sDll4-Fc) that presumably works by binding Notch receptors and
preventing their activation by endogenous Dll4 [12,13,14]. These
biopharmaceuticals showed robust antitumor activity in a variety
of human and rodent tumor xenograft models. Histology of sDll4-
Fc treated tumors revealed that the reduced tumor growth was
associated with an increase in tumor vascular density. However,
labeling with an intravascular tracer found these blood vessels to
be poorly perfused. Inefficient blood flow in the treated tumor
vessels was also reflected by the increased hypoxia observed in
tumors treated with sDll4-Fc. It appears that excessive branching
results in a highly chaotic vascular network that lacks the hierarchy
essential for efficient directional blood flow [12,13,14].
Notch signaling impact on wound healing has been previously
tested [15], revealing that inhibition of generalized Notch1
signaling leads to delayed wound healing. However the results
were not specific for the endothelium because Notch1 is known to
be expressed in several cell types involved in skin regeneration, like
keratinocytes and immune cells, among others. The endothelial
specificity of Dll4 makes it a good potential target for Notch
signaling manipulation in the endothelium. Dll4 appears to
function as anti-angiogenic factor, negatively regulating pro-
angiogenic factors, such as VEGF, and positively regulating
vascular maturation factors, like TGF-b [16,17]. Thus, anti-Dll4
therapy results in increased vascularization with decreased
vascular maturation and, therefore, decreased vascular function
[18]. The same scenario was observed in the tumor tests
[12,13,14]. We assumed that as Dll4 function is very dose-
dependent, the effect of this therapy might be adjusted by
modulating drug dosage. Here we provide in vivo evidence
supporting the use of anti-Dll4 therapy to increase vascularization
without decreasing vascular function, improving the rate of wound
healing.
Methods
Experimental animals
All animal-involving procedures in this study were approved by
the Faculty of Veterinary Medicine of Lisbon Ethics and Animal
Welfare Committee (Approval ID: PTDC/CVT/71406/2006).
The generation of Dll4
+/2 (Dll4/LacZ) mice on CD1 background
has been reported previously [10]. Dll4 conditional knockout mice
(Dll4
lox/lox) have been obtained in the lab, in collaboration with Dr.
Freddy Radtke [19]. These were crossed with VE-cadherin-Cre-
ERT2 mice, a kind gift by Dr. Ralph Adams, to produce
endothelial-specific inducible loss-of-function (eDll4
lox/lox) that is
dependent on tamoxifen administration (50 mg/kg daily for 5
days, starting on week 4). Control mice have the same genotype
but are uninduced. Dll4 conditional heterozygote mice are
Dll4
+/lox*VE-cadherin-Cre-ERT2 (eDll4
+/lox) and are induced by
tamoxifen. Control mice for both mutants have the same genotype
as the respective mutant but are uninduced. Dll4 conditional gain-
of-function mice, tetO7-Dll4 [16], were crossed with Tie2-rtTA
mice. Doxycycline (4 mg/ml in drinking water from week 4) was
given to double transgenic offspring throughout the experiment,
inducing endothelial-specific transgene expression (eDll4OE). The
control mice have the same Dll4 gain-of-function (GOF)
conditional genotype but were not induced with doxycycline. In
the therapeutical trials sDll4-Fc (soluble Dll4 extracellular domain
fused to human IgG1 Fc) was systemically administered by
intraperitoneal injection every 48 h to C57BL/6 mice from
experimental day 0 until endpoint. Control mice were adminis-
tered an equal volume of PBS. sDll4-Fc was produced as
previously described [12].
Cutaneous wounding procedure
Male mice of 10 to 15 weeks of age were used. A punch wound
was created on the back of each mouse as described [15]. Briefly,
the hair on the back of the mouse was shaved and two full-
thickness wounds were created on each mouse by excising the skin
and the underlying panniculus carnosus with a 4 mm dermal biopsy
punch. Wounds were measured on day 0, to serve as reference,
and periodically at each 24 h from that point onwards. Wounds
were considered to be ellipsoid in shape and measurements of the
larger (L) and smaller (S) diameters of each wound were made with
a caliper by two independent investigators. Percentages of the
initial wound areas were calculated as: [(p6L6S) on day n/
(p6L6S) on day 06100] and presented as (%). Experimental end-
point was determined as the point where the majority of mice had
wound sizes below 10% of the original size (,0,4 mm diameter),
as at that point measuring error was considered to outweigh
measuring accuracy. Since the end-point varied for each genetic
background, the choice of intermediate days for analysis was based
on two time points per experiment where wound sizes were found
to be more different between experimental groups.
Tissue preparation and immunohistochemistry
On each end-point mice were sacrificed and wounds were
recovered. Biopsies were fixed in 4% paraformaldehyde (PFA)
solution at 4uC for 1 h, cryoprotected in 15% sucrose, embedded
in 7,5% gelatine, frozen in liquid nitrogen and cryosectioned at
20 mm. Double fluorescent immunostaining to platelet endothelial
cell adhesion molecule (PECAM) and pericyte marker alpha
smooth muscle actin (a-SMA) was performed on tissue sections to
examine wound vascular density and vessel maturity. Rat
monoclonal anti-mouse PECAM (BD Pharmingen, San Jose,
CA) and rabbit polyclonal anti-mouse a-SMA (Abcam, Cam-
bridge, UK) were used as primary antibodies and species-specific
conjugated with Alexa Fluor 488 and 555 (Invitrogen, Carlsbad,
CA) were engaged as secondary antibodies. Tissue sections were
incubated with primary antibody overnight at 4uC and secondary
antibody for 1 hour at room temperature. Nuclei were counter-
stained with 49, 6-diamidino-2-phenylindole dihydrochloride
hydrate (DAPI; Molecular Probes, Eugene, OR). Fluorescent
immunostained sections were examined under a Leica DMRA2
fluorescence microscope with Leica HC PL Fluotar 10 and 20X/
0,5 NA dry objective, captured using Photometrics CoolSNAP
HQ, (Photometrics, Friedland, Denmark), and processed with
Metamorph 4.6–5 (Molecular Devices, Sunnyvale, CA). Morpho-
metric analyses were performed using the NIH ImageJ 1.37v
program. Vessel density corresponds to the percentage of each
tumor section field occupied by a PECAM-positive signal (as
determined by the percentage of white pixels per field after
transforming the RGB images into binary files). As a measure of
vascular maturity, mural cell recruitment was assessed by
quantitating the percentage of PECAM-positive structures lined
by a-SMA-positive coverage.
Vascular perfusion and extravasation
To mark vessel perfusion, tribromoethanol anesthetized mice
were injected with biotin-conjugated lectin from Lycopersicon
esculentum (100 mg in 100 ml of PBS; Sigma, St. Luis, MO) via
caudal vein and allowed to circulate for 5 minutes before vessel
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were collected and processed as presented above. Tissue sections
(20 mm) were stained with rat monoclonal anti-mouse PECAM
(BD Pharmingen, San Jose, CA), followed by Alexa 555 goat anti-
rat IgG (Invitrogen, Carlsbad, CA). Biotinylated lectin was
visualised with Streptavidin-Alexa 488 (Invitrogen, Carlsbad,
CA). The images were obtained and processed as described
above. Wound perfusion was quantified by determining the
percentage of PECAM-positive structures that were colocalized
with Alexa 488 signals. To analyze vascular extravasation
tribromoethanol anesthetized mice were injected with 1% Evans
Blue solution (Sigma, St. Luis, MO) via caudal vein and allowed to
circulate for 5 minutes before transcardial vessel perfusion with
4% PFA in PBS for 3 minutes. Evans Blue is red fluorescent and
extravasation was visualized in contrast to green fluorescent
vascular structures and compared between groups [20].
Quantitative transcriptional analysis
Biopsies were recovered by dissecting wound tissue from
experimental mice and snap frozen in liquid nitrogen until RNA
extraction (Qiagens RNeasy). Using a SuperScript III FirstStrand
Synthesis Supermix qRTPCR (Invitrogen, Carlsbad, CA), first-
strand cDNA was synthesized from total RNA. Real-time PCR
analysis was performed as described [16], using specific primers.
Primer pair sequences are available on request. Gene expression
was normalized to b-actin.
Statistical analyses
Data processing was carried out by engaging Statistical Package
for the Social Sciences version 17.0 (SPSS v. 17.0; Chicago, IL).
Statistical analyses were performed using Mann-Whitney-Wil-
coxon test. All results are presented as mean 6 SEM. P-
values,0,05 and ,0,01 were considered significant (indicated in
the Figures with *) and highly significant (indicated with **),
respectively.
Results
Dll4 signaling inhibition leads to antagonistic effects on
wound healing
The study of the impact of Dll4 signal modulation was initially
carried out using genetic mouse models of Dll4 loss- and gain-of-
function. Wound healing assays on an endothelial-specific Dll4
overexpressing mouse line (eDll4OE) and an endothelial-specific
Dll4 conditional knockout mouse line (eDll4
lox/lox) were anticipated to
provide some insight on the role of Dll4 in regulating adult neo-
angiogenesis. We performed daily wound area measurements and
evaluated vascular density in the granulation tissue of the wound
(Fig. 1A). Wound healing was impaired in both eDll4OE and
eDll4
lox/lox mice (Fig. 1B, D). Significantly delayed wound healing
was observed in eDll4OE mice as early as day 1 and was
maintained until day 4, when wounds were reduced to around
10% of their original size. Over a 5-day period, there was a 1 to
1,5 days delay in wound healing in eDll4OE mice compared to
controls. Histological analysis on days 2 and 5 revealed that
eDll4OE mice had approximately 40% lower vascular density in
the wound region than controls (Fig. 1C). Absolute vascular
density values increased over the period of regeneration in both
groups but the difference between groups was maintained or
slightly increased (data not shown). Wound healing was also
delayed in eDll4
lox/lox mice (Fig. 1D), which was statistically
significant at day 2 and persisted. Overall there was a 2 to 3 days
delay compared to control group over a 7-day period. Histological
analysis on days 2, 4 and 7 revealed a large increase in vascular
density throughout the experimental period in eDll4
lox/lox mice
(Fig. 1E), consistent with the previous report that Dll4 loss
promotes angiogenesis [12,21].
In contrast to the initial findings, wound-healing assays on
Dll4
+/2 mice revealed that regeneration was improved when
compared with control Dll4
+/+ mice (Fig. 1F). Differences in
wound size became statistically significant by day 2 and persisted
until day 6. From day 2 until day 6 the wound healing in Dll4
+/2
mice presented a steady 2-day advance over control mice.
Histological analysis revealed an increase in vascular density that
could be seen in Dll4
+/2 mice as early as day 2 (Fig. 1G). This
difference in vascular density was maintained throughout the
wound recovery period, even though absolute vascular density
values increase in both experimental groups (data not shown).
To confirm that the improvement in wound healing observed in
Dll4
+/2 mice was due to the change in vasculature, and not others
factors such as the inflammatory response [22], further experi-
ments with endothelial-specific conditional Dll4 heterozygotes
(Dll4
+/lox*VE-Cadherin-CreERT2 - from now on eDll4
+/lox) were
carried out. Results revealed that in eDll4
+/lox mice wounds
regenerated faster than in the respective controls, in a similar
fashion to what was described for Dll4
+/2 mice. A two-day
advance in wound closure of eDll4
+/lox was established by day 2
and was maintained until the endpoint (Fig. 2A). Vascular density
evaluation confirmed identical differences in relation to wild type
controls in both eDll4
+/lox and Dll4
+/2 (Fig. 2B,C). Pro-
inflammatory gene expression at day 2, during the inflammatory
phase of wound closure, was tested in both Dll4
+/2 and eDll4
+/lox
mice. This would allow the identification of a possible influence of
Dll4 function in mediating the inflammatory response indepen-
dent of the vascular phenotype. This possible effect was tested by
RT-PCR analysis of wound biopsies to evaluate the expression of
pro-inflammatory genes. Results showed that monocyte/macro-
phage chemo attractant MCP1 had reduced expression in both
eDll4
+/lox and Dll4
+/2. Pro-inflammatory genes, such as ICAM,
VCAM and MIP2, were also downregulated in both eDll4
+/lox and
Dll4
+/2 mice. Markers of macrophage activation iNOS, PTX3
and Id1 had reduced expression in both eDll4
+/lox and in Dll4
+/2
(Fig. 2D). We then evaluated the gene expression profile of the
same inflammation-related genes in the Dll4 mutant mice that
showed impaired regeneration profile, eDll4
lox/lox and Dll4OE,a s
this would allow us to correlate changes in the inflammatory
profile of wounds to their regeneration profile. Results showed that
the expression of pro-inflammatory genes was upregulated in both
eDll4
lox/lox and Dll4OE (Fig. S1).
sDll4-Fc therapy has antagonistic effects on wound
healing depending on dosage
Inflammatory gene expression in eDll4
+/lox indicated that Dll4
function in the endothelium was the most important factor
accounting for the observed improvements in wound closure.
eDll4
+/lox (and Dll4
+/2) and eDll4
lox/lox mice can give rise to
opposing phenotypes despite both being loss-of-function mutants
and both displaying a pro-angiogenic phenotype. We therefore
proposed that dosage of the inhibitor (soluble Dll4-Fc) may mimic
the Dll4 dose response observed in Dll4 deficient mouse lines
allowing us to define the dosage of sDll4-Fc that promotes wound
healing. sDll4-Fc therapy was tested in C57BL/6 mice using
dosages from 0,025 mg/kg to 2,5 mg/kg. Mice were injected on
day 0, after wounding, and every 2 days until the endpoint. Lower
dosages, like 0,025 mg/kg, 0,05 mg/kg and 0,1 mg/kg, were
observed to accelerate wound healing (Fig. 3A). Statistical
significance in wound size difference was achieved as early as
day 1 in the 0,05 mg/kg dosage group and day 2 in the 0,025 mg/
Inhibition of Dll4 Promotes Wound Healing
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the regeneration period. From day 2 until day 5 a 1 to 1,5 day
advantage in wound size was observed in treated mice over control
mice, with the 0,05 mg/kg dosage group displaying the largest
benefit. Testing with higher dosages, such as 0,5 mg/kg, 1 mg/kg
and 2,5 mg/kg revealed an opposite effect delaying wound healing
(Fig. 3B). Statistical significance in wound size difference was
observed by day 1 in the 1 mg/kg and 2,5 mg/kg dosage groups
and maintained until endpoint. Dosage 0,5 mg/kg was considered
to originate wound healing statistically indistinguishable from that
of control mice. Dosage 1 mg/kg displayed a 0,5 to 1 day delay in
wound healing, while the 2.5 mg/kg dosage displayed a 1 to 1,5
day delay, over a 6-day period. To understand how opposing
effects on wound regeneration were generated by modulating
sDll4-Fc therapy dosage we analyzed vascular density on days 2, 4
and 6. This revealed that in all dosage groups there was increased
vascular density, the degree of which was in direct relationship
with the increase in dosage (Fig. 4 A,C,D,E). Dosages that led to
improved wound healing caused increases in vascular density of 20
to 50%, while dosages that led to impaired wound healing caused
much larger increases of 70 to 300%.
Neo-vasculature in sDll4-Fc treated mice is less mature
but has variable perfusion and extravasation depending
on dosage
Normal neo-vascularization involves the proliferation and
progression of pre-existing endothelium into stressed areas. That
newly formed vasculature has to mature, becoming more stable.
This is achieved mainly by inducing the differentiation and
recruitment of smooth muscle cells and pericytes. We analyzed the
wound basin neo-vasculature of mice treated with 0,05 mg/kg and
2,5 mg/kg of sDll4-Fc, the dosages that led to the best and worst
result in wound healing, and the respective control, for the
presence of vascular smooth muscle cells. While PBS-injected mice
had a normal coverage of smooth muscle, sDll4-Fc injected mice
had a 3-fold reduced coverage in both doses (Fig. 4B, C, D and E).
This effect became evident as early as Day 2 and persisted
throughout wound regeneration. By comparison, all Dll4 loss-of-
function mutants analyzed in this work produced similar results to
those obtained with sDll4-Fc showing reduced presence of
perivascular cells, while Dll4OE mutants displayed increased
recruitment of perivascular cells (Fig. S2).
Since one of the hallmark observations after sDll4-Fc therapy on
tumors was the poor perfusion of newly formed vasculature [12],
lectin perfusion (Fig. 5A,B) and Evans Blue vascular extravasation
(Fig. 5C) testing were carried out in the wound healing setting.
The 0,05 mg/kg dosage revealed no significant improvement in
the percentage of lectin perfused blood vessels, and a low level of
vascular extravasation, relative to control. The 2.5 mg/kg dosage
revealed much-decreased lectin perfusion and very pronounced
Evans Blue extravasation. These results confirm that the impaired
maturation of the neo-vasculature in sDll4-Fc treated mice is
dosage-dependent and that the effectiveness of blood circulation to
affected tissues varies directly with the degree of neo-vasculature
maturation. For comparison purposes, Dll4
+/2 and eDll4
+/lox
neovasculature had a lectin perfusion index that was not
statistically different to their respective controls, and slightly
higher Evans Blue extravasation than controls. Dll4 mutants with
impaired wound healing profile, eDll4
lox/lox and Dll4OE, both
revealed reduced lectin perfusion, while eDll4
lox/lox displayed a very
high level of vascular extravasation and Dll4OE showed an almost
normal level of vascular extravasation (Fig. S3A, B).
Dll4 modulation has no effect on the skin adjacent to the
wound
We have described that sDll4-Fc therapy can affect the
vasculature of wounds and therefore, influence the regenerative
profile. Since our approach is not targeted to the affected region
we decided to investigate if the vasculature of skin adjacent to the
wound site would be equally affected by sDll4-Fc therapy in either
high- or low-dosage form. PECAM and SMA immunofluores-
cence (Fig. 6A–F) revealed that outside the wound the vasculature
was largely unaffected during the therapy period. Vascular density
and smooth muscle cell coverage indexes of the skin adjacent to
the wound in mice treated with 0,05 mg/kg and 2,5 mg/kg sDll4-
Fc did not differ statistically at endpoint from PBS-treated mice
(Fig. 6G,H). Microscopic analysis of surrounding tissues also did
not reveal any histological changes to control (Fig. 6I–K).
Effect of Dll4 modulation on the expression of vascular
genes
To help the identification of the mechanistic causes behind the
observed phenotypes the expression of selected genes in the wound
area was characterized by RT-PCR. RNA was extracted from
wound biopsies taken from both genetic models and sDll4-Fc
treated mice. Expression levels were normalized to PECAM-1
mRNA levels [23] to compensate for variations in vascular density
between samples. In the genetic models (Fig. 7A), Dll4 expression
levels corresponded to the expectation, with a 4-fold increase in
the Dll4OE mice and a reduction to 0,56 in the Dll4
+/2 and to
0,136in the eDll4
lox/lox mice. Jagged1 expression levels decreased in
the loss-of-function models and increased in the Dll4OE mice.
Hey2, the main known Notch signaling effector in the endothelium
[24], displayed higher expression levels in eDll4OE and lower
expression levels in the loss-of-function models, confirming that
the Notch pathway is being affected by the induced Dll4
mutations. Hey1 gene expression levels were found to vary
similarly to Hey2 except that the differences to respective controls
were smaller. Rbp-J is the principal mediator of NICD function in
the regulation of Notch effector genes expression regulation [25].
Rbp-J expression levels were found to be upregulated in eDll4OE
and downregulated in the Dll4 loss-of-function models. Ephrin-B2
is known to be downstream of Notch signaling in embryonic
Figure 1. Wound regeneration in Dll4 mouse mutants. A) Hematoxylin-Eosin staining of a wound biopsy cryosection. Lines delimit the wound
margins, (*) denotes granulation tissue. All immunofluorescence images relate to neo-vasculature formed inside granulation tissue. B) Comparisono f
eDll4OE mice with uninduced controls. Graphic depicting the correlation between wound areas in each experimental day relative to the wound area
measured on Day 0, Wound regeneration is delayed in eDll4OE mice. C) Vascular density is decreased in granulation tissue of eDll4OE mice, relative to
uninduced controls throughout the experiment. D) Comparison of eDll4
lox/lox mice with uninduced controls. Graphic depicting the correlation
between wound areas in experimental days relative to wound areas measured on Day 0, Wound regeneration is delayed in eDll4
lox/lox mice. E)
Vascular density is increased in granulation tissue of eDll4
lox/lox mice, relative to uninduced controls throughout the experiment. F) Graphic depicting
the correlation between wound areas in experimental days relative to wound areas measured on Day 0, comparing Dll4
+/2 mice with wild type (WT)
controls. Wound regeneration is accelerated in Dll4
+/2 mice. G) Vascular density is increased in granulation tissue of Dll4
+/2 mice, relative to WT
controls throughout the experiment. H) Representative anti-PECAM immunofluorescence images of neo-vasculature in granulation tissue of above
described genetic models at endpoint. * In graphics represents p,0,05.
doi:10.1371/journal.pone.0029863.g001
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and endothelial identity [26]. Ephrin-B2 expression was decreased
in Dll4
+/2 and eDll4
lox/lox mice and increased in eDll4OE mice,
corroborating the vascular maturation results obtained by
immunofluorescence. EphB4 encodes the venous-specific cognate
receptor for Ephrin-B2 [27]. EphB4 expression was upregulated in
Figure 2. The wound regeneration profile of endothelial specific Dll4 heterozygous mice (eDll4
+/lox) is similar to that of constitutive
Dll4 heterozygous mice (Dll4
+/2) and both share a reduced inflammatory response when compared to Dll4 WT mice. A) Comparison of
eDll4
+/lox mice with uninduced controls. Graphic depicting the correlation between wound areas in each experimental day relative to the wound area
measured on Day 0, Wound regeneration is accelerated in eDll4
+/lox mice in a similar way as in the Dll4
+/2 mice. B) Vascular density is increased in
granulation tissue of eDll4
+/lox mice, relative to uninduced controls throughout the experiment. C) Representative anti-PECAM immunofluorescence
images of neo-vasculature in granulation tissue of eDll4
+/lox and uninduced controls at endpoint. D) Differential gene expression in Dll4
+/2 versus WT
and eDll4
+/lox versus uninduced control wounds of inflammation-related genes at day 2. Dll4 expression is confirmed to be approximately 0,5-fold in
both cases, relative to their respective controls, and statistically similar. Inflammation-related genes have reduced expression in both mutant mice,
probably resulting from the improved condition of the mutant mice wounds that regenerate faster. * In graphics represents p,0,05.
doi:10.1371/journal.pone.0029863.g002
Figure 3. Modulation of sDll4-Fc dosage can achieve both improved or impaired wound regeneration through low- or high-dosage
inhibition. A) Graphic depicting the correlation between wound areas in experimental days relative to wound areas measured on Day 0, comparing
mice treated with sDll4-Fc dosages lower than 0,1 mg/kg with untreated (sham treated) controls. Wound regeneration is accelerated in mice treated
with sDll4-Fc dosages lower than 0,1 mg/kg. B) Graphic depicting the correlation between wound areas in experimental days relative to wound areas
measured on Day 0, comparing mice treated with sDll4-Fc dosages higher than 0,5 mg/kg with controls. Wound regeneration is delayed in mice
treated with sDll4-Fc dosages higher than 0,5 mg/kg.
doi:10.1371/journal.pone.0029863.g003
Inhibition of Dll4 Promotes Wound Healing
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lox/lox and downregulated in Dll4OE mice. Dll4 is a known
regulator of VEGF signaling, having specific control over the
expression of its transmembrane receptors in the endothelium
[28]. Vegf-a expression levels were decreased in Dll4
+/2 mice, while
they were increased in the eDll4
lox/lox and eDll4OE mice, which had
delayed wound regeneration, probably accounting for reduced
hypoxia in wounds with improved regeneration. Dll4 is a known
suppressor of VEGF-C/VEGFR3 signaling [29]. The expression
of Vegf-c in the wounds was augmented in both Dll4
+/2 and
eDll4
lox/lox mice but in eDll4OE mice the difference was found to be
not significant. VEGF receptor expression analysis revealed that
eDll4OE mice had lower expression of Vegfr2 and Vegfr3, both of
which mediate VEGF signaling, and higher expression of Vegfr1,
which acts mainly as a VEGF trap [30] and blocks VEGF-A
mediated pro-angiogenic signal. In the loss-of-function models
VEGFRs expression varied in the opposite direction, with
decreased Vegfr1 expression and increased Vegfr2 and Vegfr3
expression and thus increased angiogenic potential. Tie2 loss-of-
function is associated with a decrease in smooth muscle cell
recruitment [31]. Expression of Tie2 in our genetic models reflects
this effect, being lower in both Dll4
+/2 and eDll4
lox/lox mice, which
had less smooth muscle, and increased in eDll4OE mice, which had
an higher than normal number of smooth muscle cells. Lyve1 is a
known lymphatic endothelial cell-specific gene [32]. Recently,
Dll4 blockade was associated with disruption of post-natal
lymphatic development [33]. Lyve1 expression was downregulated
in eDll4
lox/lox mice and upregulated in eDll4OE. More importantly
Lyve1 expression in eDll4
+/lox, which displayed accelerated wound
healing, was found to be near normal levels.
In the mice subjected to sDll4-Fc therapy (Fig. 7B), endogenous
Dll4 expression decreased with dosages up to 0,1 mg/kg and
increased with dosages greater than 0,5 mg/kg, reflecting Vegf-a
expression levels, one of the main inducers of Dll4 expression. Hey2
expression levels confirmed the inhibitory effect of sDll4-Fc on
Notch signaling, being lower in all dosages and showing a strong
dependency on the dosage of the inhibitor, again confirming that
Figure 4. Wounds treated with sDll4-Fc have increased vascular density but decreased vascular maturation in direct proportion to
the dosage level. A) Vascular density is increased in granulation tissue of mice treated with sDll4-Fc, being directly proportional to the dosage
increase, when compared to controls throughout the experiment. B) Vascular smooth muscle cell coverage is decreased about 3-fold in relation to
PBS-injected control mice throughout the experimental days in both tested groups. C,D,E) Representative anti-PECAM and anti-SMA
immunofluorescence images of neo-vasculature in granulation tissue of wounds treated with (D) 0,05 mg/kg or (E) 2,5 mg/kg compared with
control mice injected with PBS (C), in days 2, 4 and 6. sDll4-Fc therapy leads to decreased smooth muscle cell recruitment and increased vascular
density that is directly proportional to the administered dosage. * In graphics represents p,0,05.
doi:10.1371/journal.pone.0029863.g004
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Notch signaling. Jagged1, Hey1 and Rbp-J expression values were
similar to that of Hey2. Ephrin-B2 expression also responded
linearly to increasing sDll4-Fc inhibition, showing greater decrease
with increasing sDll4-Fc dosage. In contrast EphB4 expression
increased in direct relation to sDll4-Fc dosage. Vegf-c expression
also increased in direct relation to sDll4-Fc dosage. In regard to
the VEGF receptors, expression of Vegfr1 decreased (in indirect
relation to sDll4-Fc dosage) and Vegfr2 and Vegfr3 increased in
direct relation to sDll4-Fc dosages. Tie2 expression levels
decreased in all sDll4-Fc dosages, showing an inverse relation to
sDll4-Fc dosages. Lyve1 expression values were always downreg-
ulated, except at the 0,05 mg/kg sDll4-Fc dosage, with expression
decreasing with increasing sDll4-Fc dosages.
Figure 5. Low-dosage sDll4-Fc does not affect perfusion levels and leads to only a small increase in extravasation while higher
dosages cause decreased perfusion and highly increased extravasation. A) Representative anti-PECAM and anti-Lectin immunofluores-
cence images of neo-vasculature in granulation tissue of wounds treated with 0,05 mg/kg or 2,5 mg/kg compared with control mice injected with
PBS, in day 6. B) The percentage of lectin-perfused blood vessels is similar between PBS- and 0,05 mg/kg sDll4-Fc injected mice but since vascular
density is increased in the latter this result represents an effective increase in vascular function in the wound basin. Vascular perfusion is highly
decreased in wounds of mice injected with 2,5 mg/kg sDll4-Fc. C) Representative anti-PECAM and Evans Blue immunofluorescence images of neo-
vasculature in granulation tissue of wounds treated with 0,05 mg/kg or 2,5 mg/kg compared with control mice injected with PBS, in day 6. Vascular
extravasation is highly increased in wounds of mice injected with 2,5 mg/kg sDll4-Fc but displays only a small increase in the case of 0,05 mg/kg
sDll4-Fc injected mice. * In graphics represents p,0,05.
doi:10.1371/journal.pone.0029863.g005
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The importance of Dll4 was first described by its function in the
establishment of endothelial identity and in the regulation of
vascular morphogenesis in embryonic vascular development.
Experimental data place Dll4 in the middle of a loop of
angiogenesis regulatory pathways. Dll4 was found to be one of
the key players acting as negative regulator of angiogenesis,
working to maintain the fine balance between vascular progression
and vascular maturation/quiescence [34]. This important function
has led to the development of therapies blocking Dll4 function for
tumor therapy. Dll4 inhibition, and sDll4-Fc therapy in particular,
have shown potential in controlling tumor growth, even in cases
when tumors have gained resistance to anti-VEGF therapies
[12,13]. The mechanism of action of this therapy is strikingly
different to that of classic anti-angiogenic therapies, which work by
reducing the ability of a tumor to induce the growth of new blood
vessels or by reducing the ability of blood vessels to sprout and
form the neo-vasculature in the tumor. Dll4 inhibition works by
increasing vascular density through uncontrolled growth, resulting
in the new vasculature being disorganized, inefficient and poorly
perfused, leading to an increase in tumor hypoxia and reduction in
tumor growth [35].
As the embryonic lethal haploinsufficiency of Dll4 is indicative
of a strong functional dosage-dependence, we hypothesized that
the non-functional nature of the tumoral neo-vasculature observed
in anti-Dll4 therapy [12,21] was a consequence of the high dosage
of Dll4 inhibitor used and that by modulating therapy dosage it
might be possible to achieve a functional pro-angiogenic effect.
Dll4-based therapy could then be used to treat conditions where
the formation of new blood vessels is essential and beneficial, like
wound healing. In this case, angiogenesis starts almost immedi-
ately following injury and is important for the formation of
granulation tissue, to supply oxygen and nutrients to growing
tissues and as a means to deliver inflammatory cells to the wound
site [4].
Wound healing was tested on murine genetic models of Dll4
gain- and loss-of-function. Results revealed that Dll4 heterozygote
mice (both Dll4
+/2 and eDll4
+/lox) presented accelerated wound
regeneration with improved vascular density as well as near-
normal percentage of perfused blood vessels, whereas eDll4
lox/lox
and eDll4OE presented delayed wound healing. In the first case it
was related to highly increased vascular density and in the latter
related to a reduction in vascular density, both phenotypes leading
to reduced tissue perfusion. Since improved wound regeneration
observed in the Dll4
+/2 mice was caused by a constitutive
mutation and previous works described a possible link between
Dll4 and inflammatory macrophages [22], we decided to test if an
equivalent endothelial-specific mutation could give rise to the same
phenotype. Results with eDll4
+/lox mice showed a similar wound
regeneration profile to that of Dll4
+/2 mice. This indicates that at
least the principal contributor to the observed phenotype was the
loss of Dll4 function in the endothelium. Nevertheless we
measured by RT-PCR the expression levels of several regulators
of inflammatory function. The expression profile indicated that in
both Dll4
+/2 and eDll4
+/lox there is a reduction in the expression of
macrophage chemoattractants, regulators of monocyte/macro-
phage infiltration and markers of macrophage activation. Since
the results are not statistically different between eDll4
+/lox and
Dll4
+/2 we can infer that the differences in the inflammatory
profile of both mutant mouse lines is unrelated to Dll4 expression.
The gene expression levels of the same inflammatory profile
markers are increased in both the eDll4
lox/lox and Dll4OE mice with
opposing Dll4 mutations and delayed wound regeneration. So, the
Figure 6. Skin adjacent to the wound site suffers no alterations
independently of the dosage used in the sDll4-Fc therapy. Anti-
PECAM (red) and anti-SMA (green) immunofluorescence of A) PBS-, B)
0,05 mg/kg sDll4-Fc- or C) 2,5 mg/kg sDll4-Fc-treated mice D,E,F)
Representative anti-PECAM immunofluorescence images of neo-vascu-
lature in unaffected skin adjacent to the wound site. G) Vascular density
in unaffected skin is not statistically different between PBS-, 0,05 mg/
kg- and 2,5 mg/kg-treated mice. The same happens for perivascular cell
coverage H). I–J) Hematoxylin and eosin staining of 20 mm cryosections
of PBS-, 0,05 mg/kg- and 2,5 mg/kg-treated mice wounds depicting the
wound size and unaffected adjacent skin at day 6.
doi:10.1371/journal.pone.0029863.g006
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an improved or impaired wound regeneration status, not a specific
response to the Dll4 mutations. These results confirmed that
different levels of Dll4 blockade give rise to either an improvement
or impairment in wound regeneration, depending on whether the
increased angiogenesis leads to functional or non-functional blood
vessels.
The next step was to test different dosages of sDll4-Fc therapy in
surgically wounded wild-type mice. Results showed that lower
dosages, between 0,025 mg/kg and 0,1 mg/kg accelerate wound
regeneration by inducing productive angiogenesis that is function-
al and causes an improvement in blood flow in the wound area
without affecting the surrounding quiescent vasculature. Compar-
ing results from different dosages, 0,025 mg/kg, 0,05 mg/kg and
Figure 7. Differential gene expression in wounds affected by A) Dll4 genetic alterations or B) sDll4-Fc therapy administration. Gene
expression analysis of wound tissues was performed by RT-PCR for indicated genes involved in angiogenesis. Gene expression levels were normalized
for b-actin levels. Error bars represent SD. * in graphics represents p,0,05.
doi:10.1371/journal.pone.0029863.g007
Inhibition of Dll4 Promotes Wound Healing
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e298630,1 mg/kg revealed that while all dosages tested gradually
improved vascular density, the transition from functional to non-
functional angiogenesis appears to occur when the dosage
increases from 0,05 to 0,1 mg/kg. This is based on the observation
that wound healing is accelerated when the dosage increases from
0,025 to 0,05 mg/kg, as a result of increased vascular function, but
slowed down when it is further increased from 0,05 to 0,1 mg/kg.
This indicates that the transition from functional to non-functional
angiogenesis is a result of vascular inefficiency arising from
increasing vascular density and inability to form proper blood
vessel lumens and perivascular wall. With higher dosages, ranging
from 0,5 to 2,5 mg/kg of sDll4-Fc, wound regeneration was
progressively delayed over control mice, as increasingly higher
vascular densities led to decreased vascular maturation, decreased
perfusion and increased vascular extravasation and therefore
reduced vascular function. Most importantly, in sDll4-Fc treated
mice the vasculature of the skin adjacent to the wound site
remained unaffected when compared to PBS-treated mice. This
result indicates that sDll4-Fc therapy specifically targets sites of
active angiogenesis, where Dll4 function is most important to
regulate vascular morphogenesis. A recent work [36] described
that prolonged (over 8 weeks long) therapy with high dosages of
Dll4 inhibitors (much higher than any of the dosages used in this
work) can lead to low frequency non-lethal subcutaneous vascular
neoplasms and histopathological changes in the liver. We have not
observed subcutaneous tumors in our sDll4-Fc treated mice or
Dll4 mutant mice for the duration of the experiments. It is possible
that the lesions cited are also dosage-dependent or due to long
term Dll4 blockade. Our results indicate that at low dosages and
for short term therapy the risk of such secondary effects should be
minimal.
Gene expression analysis confirmed the existence in the wound
healing process of a regulatory loop between VEGF signaling and
Dll4/Notch signaling, where Dll4/Notch signaling blockade leads
to a reduction in Vegfr1 and an increase in Vegfr2 and Vegfr3
expression, increasing vascular response to VEGF-A and –C
expression from surrounding stroma [29,37]. Jagged1 is a member
of the Notch ligand family and is present in arterial endothelial
cells and vascular smooth muscle cells [39]. Jagged1 expression was
found to be directly related to Dll4 function, which could reveal a
novel regulatory feedback loop between Dll4 and Jagged1 where
increasing Dll4 function potentiates Jagged1 expression that then
negatively regulates Dll4/Notch signaling [24]. Ephrin-B2 is
involved in the activation of angiogenesis and recruitment of
perivascular cells to neo-vasculature [38,39], acting downstream of
VEGF and Notch signaling while at the same time acting as a
regulator of VEGF-R2 and –R3 internalization and function
[40,41]. It is expressed in arterial endothelium and in smooth
muscle cells. Ephrin-B2 expression was found to be directly related
to Dll4 function and could indicate one way through which Dll4/
Notch signaling regulates vascular smooth muscle cell recruitment.
EphB4 expression is opposite to Ephrin-B2 expression and increases
with sDll4-Fc dosage. This could also indicate that higher dosages
of sDll4-Fc lead to a shift to venous neo-vasculature, while lower
dosages have no impact on arterial-venous proportion. The Tie2
receptor is considered to be endothelial-specific, while its cognate
ligand Ang1 is expressed mainly by perivascular and mural cells,
acting as a paracrine signal to the endothelium. Loss-of-function
studies revealed a phenotype with defective angiogenesis and
reduced coverage and detachment of smooth muscle cells and
pericytes [42]. sDll4-Fc therapy leads to a dosage-dependent
reduction in Tie2 expression, demonstrating the Ang1/Tie2
pathway involvement in the regulation of vascular maturation
and quiescence downstream of Dll4/Notch signaling. It was shown
recently that Dll4 blockade could inhibit lymphatic vessel assembly
[33]. Our expression results revealed that while that is true for
high dosage Dll4 inhibition, in the 0,05 mg/kg sDll4-Fc dosage
the reduction in Lyve1 expression, a lymphatic endothelial cell
marker is not significantly different to the control.
A role for Notch signaling in wound healing [15] has previously
been suggested by use of a Notch1 knockdown mouse line as well
as small molecule inhibitor of Notch signaling (GSI treatment).
Those results indicated that Notch1 inhibition led to a delay in
wound regeneration but failed to report on the wound vascular
phenotype. Besides endothelial cells, Notch1 is present in skin, at
least in keratinocytes as well as in various immune cells, making it
difficult to separate the impact of the mutation in the different cell
systems and how they integrate to display a given phenotype.
Together, our results present evidence that endothelial Notch
signaling is a potential target for wound regeneration therapies
through its ligand Dll4. Low-dosage sDll4-Fc accelerates wound
regeneration by creating a neo-vasculature that has a slight
increase in vascular density while keeping nearly normal perfusion
of the blood vessels and arterial-venous phenotype, without
affecting lymphatic vasculature. Overall low-dosage sDll4-Fc
therapy leads to an effective increase in local blood supply to the
wound site, not affecting lymphatic drainage or the quiescent
vasculature.
Supporting Information
Figure S1 Dll4 mutants with impaired wound regeneration
share a pro-inflammatory profile. Differential gene expression in
Dll4OE and eDll4
lox/lox versus respective uninduced control wounds
of inflammation-related genes at day 2. Inflammation-related
genes have upregulated expression in both mutant mice, probably
resulting from the impaired condition of the mutant mice wounds
that regenerate slower. * In graphics represents p,0,05.
(TIF)
Figure S2 All Dll4 loss-of-function mutants tested displayed
reduced perivascular cell recruitment, while Dll4OE mice revealed
an opposite phenotype. * In graphics represents p,0,05.
(TIF)
Figure S3 A) The percentage of lectin-perfused blood vessels is
not statistically different to control levels in Dll4
+/2 and eDll4
+/lox,
while being highly reduced in eDll4
lox/lox and Dll4OE. B) Evans
Blue extravasation is slightly increased in Dll4 heterozygote
models, highly increased in eDll4
lox/lox and near normal levels in
Dll4OE. * In graphics represents p,0,05.
(TIF)
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